Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2883-2898

  Quan, Ping ^a   Moinfar, Farid ^a,b   Kufferath, Iris ^a   Absenger, Markus ^a   Kueznik, Tatjana ^a   Denk, Helmut ^a   Zatloukal, Kurt ^a   Haybaeck, Johannes ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

Author keywords

Combination therapy; Endometrial stromal sarcoma; PI3K mTOR pathway; SAHA

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HISTONE DEACETYLASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; VORINOSTAT; EIF4EBP1 PROTEIN, HUMAN; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; SARCOMA CELL; APOPTOSIS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENDOMETRIUM TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PI3K/MTOR PATHWAY; SIGNAL TRANSDUCTION; THERAPY; TUMOR CELL CULTURE; WESTERN BLOTTING;

COMBINATION THERAPY; ENDOMETRIAL STROMAL SARCOMA; PI3K/MTOR PATHWAY; SAHA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASES; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SARCOMA, ENDOMETRIAL STROMAL; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84904509022     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr., Judson PL, Carson LF and Boente MP: Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol 95: 632-636, 2004.
2. Beck TL, Singhal PK, Ehrenberg HM, Rose PG, Lele SB, Krivak TC and McBee WC Jr.: Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. Gynecol Oncol 125: 141-144, 2011.
3. Moinfar F, Azodi M and Tavassoli FA: Uterine sarcomas. Pathology 39: 55-71, 2007.
4. Amant F, Woestenborghs H, Vandenbroucke V, Berteloot P, Neven P, Moerman P and Vergote I: Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecol Oncol 103: 1137-1140, 2006.
5. Shubassi G, Robert T, Vanoli F, Minucci S and Foiani M: Acetylation: a novel link between double-strand break repair and autophagy. Cancer Res 72: 1332-1335, 2012.
6. Helman LJ and Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer 3: 685-694, 2003.
7. Hrzenjak A, Moinfar F, Tavassoli FA, Strohmeier B, Kremser ML, Zatloukal K and Denk H: JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular analysis by reverse transcriptase-polymerase chain reaction optimized for paraffin-embedded tissue. J Mol Diagn 7: 388-395, 2005.
8. Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics 3: 28-37, 2008.
9. Gan YH and Zhang S: PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol 45: e150-154, 2009.
10. Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovee JV, Wang WL, Lev D and Lazar AJ: Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 25: 212-221, 2011.
11. Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, Czerwitzki J, Steiner S, Renner M, Penzel R, Koch A, Larsson O, Tanaka S, Kawai A, Schirmacher P, Mechtersheimer G, Wardelmann E, Buettner R and Hartmann W: Phosphatidy-linositol-3'-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 129: 1564-1575, 2010.
12. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP and Cordon-Cardo C: The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13: 748-753, 2007.
13. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K and Denk H: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5: 2203-2210, 2006.
14. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K and Denk H: SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 216: 495-504, 2008.
15. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K and Denk H: Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer 9: 49, 2010.
16. Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
17. Perdiz D, Mackeh R, Pous C and Baillet A: The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal 23: 763-771, 2010.
18. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458, 2002.
19. Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Hazar-Rethinam M, de Long LM, Wooley K, Guminski A and Saunders NA: Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 106: 107-115, 2011.
20. DePasquale JA, Samsonoff WA and Gierthy JF: 17-beta-Estradiol induced alterations of cell-matrix and intercellular adhesions in a human mammary carcinoma cell line. J Cell Sci 107(Pt 5): 1241-1254, 1994.
21. Fantin VR and Richon VM: Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 13: 7237-7242, 2007.
22. Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283-296, 2012.
23. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA and McCubrey JA: Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27: 4086-4095, 2008.
24. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
25. Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB and Broaddus RR: Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25: 699-708, 2012.
26. Koul D: PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7: 1321-1325, 2008.
27. Moinfar F, Kremser ML, Man YG, Zatloukal K, Tavassoli FA and Denk H: Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues. Gynecol Oncol 95: 662-671, 2004.
28. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
29. Blay JY: Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 22: 280-287, 2010.
30. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562, 2009.
31. Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC and Waterfield MD: Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J 326(Pt 1): 139-147, 1997.
32. Virbasius JV, Guilherme A and Czech MP: Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J Biol Chem 271: 13304-13307, 1996.
33. Choo AY and Blenis J: Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8: 567-572, 2009.
34. Lawlor MA and Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001.